Monoclonal Antibodies May Cause Serious Harm for Patients with Alzheimer
Myloid-reducing monoclonal antibodies for patients with Alzheimer have harmful risks, such as cerebral edema, hemorrhage, serious adverse events, and death, according to a new study.
University Of Georgia United States Markh Ebell University Of Georgia Markh Ebell Food Drug Administration Clinical Benefit
Source: hcplive.com